hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-18 and is reviewed periodically as new material appears.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Occurrence === The longest-lived isotope of neptunium, 237Np, has a half-life of 2.14 million years, which is more than 2,000 times shorter than the age of the Earth. Therefore, any primordial neptunium would have decayed in the distant past. After only about 80 million years, the concentration of even the longest-lived isotope, 237Np, would have been reduced to less than one-trillionth (10−12) of its original amount. Thus neptunium is present in nature only in negligible amounts produced as intermediate decay products of other isotopes. Trace amounts of the neptunium isotopes neptunium-237 and -239 are found naturally as decay products from transmutation reactions in uranium ores. 239Np and 237Np are the most common of these isotopes; they are directly formed from neutron capture by uranium-238 atoms. These neutrons come from the spontaneous fission of uranium-238, naturally neutron-induced fission of uranium-235, cosmic ray spallation of nuclei, and light elements absorbing alpha particles and emitting a neutron. The half-life of 239Np is very short, although the detection of its much longer-lived daughter 239Pu in nature in 1951 definitively established its natural occurrence. In 1952, 237Np was identified and isolated from concentrates of uranium ore from the Belgian Congo: in these minerals, the ratio of neptunium-237 to uranium is less than or equal to about 10−12 to 1. Additionally, 240Np must also occur as an intermediate decay product of 244Pu, which has been detected in meteorite dust in marine sediments on Earth.
The primary emissions of 131I decay are thus electrons with a maximal energy of 606 keV and gammas of 364 keV. Beta decay also produces an antineutrino, which carries off variable amounts of the energy. The electrons, due to their high mean energy (190 keV, with a typical beta-decay spectrum) have a tissue penetration of 0.6 to 2 mm.
Noracymethadol (INN) is a synthetic opioid analgesic related to methadone that was never marketed. In a clinical trial of postpartum patients it was reported to produce analgesia comparable to that of morphine but with less nausea, dizziness, and drowsiness. Other side effects included salivation, ataxia, and respiratory depression that was reversible by naloxone. Similarly to many of its analogues, noracymethadol is a Schedule I controlled substance in the United States with an ACSCN of 9633 and 2013 annual manufacturing quota of 12 grammes. and is also controlled internationally under the United Nations Single Convention on Narcotic Drugs of 1961. The salts known are the gluconate (free base conversion ratio 0.633) and hydrochloride (0.903). Noracymethadol is an acetate ester of methadol and it can be said with some precision that it is either the heroin or 6-monoacetylmorphine analogue of methadol, and being a methadol it exhibits optical isomerism. The other methadols (acetylmethadol, methadol &c) have at least four optical isomers (see Orlaam).
Bitcoin (abbreviation: BTC; sign: ₿) is the first decentralized cryptocurrency. Based on a free-market ideology, bitcoin was invented in 2008 when an unknown person published a white paper under the pseudonym of Satoshi Nakamoto. Use of bitcoin as a currency began in 2009, with the release of its open-source implementation. From 2021 to 2025, El Salvador adopted it as legal tender currency before revoking it. As bitcoin is pseudonymous, its use by criminals has attracted the attention of regulators, leading to its ban by several countries. Bitcoin works through the collaboration of computers, each of which acts as a node in the peer-to-peer bitcoin network. Each node maintains an independent copy of a public distributed ledger of transactions, called a blockchain, without central oversight. Transactions are validated through the use of cryptography, preventing one person from spending another person's bitcoin, as long as the owner of the bitcoin keeps certain sensitive data secret. Consensus between nodes about the content of the blockchain is achieved using a computationally intensive process based on proof of work, called mining, which is performed by purpose-built computers. Mining consumes large quantities of electricity, with surveyed miners reporting that 52% of their electricity use came from sustainable energy sources, and has been criticized for its environmental impact.
For services to Music. David Wilkinson Cawthra, lately Director, Infrastructure Services Privatisation, British Railways Board. For services to the Railway Industry. Honor Mary Ruth Chapman, Partner, Jones Lang Wootton. For services to the Property Industry. William Herman MacKillop Clark, lately Head, Operational Re-organisation Division, Crown Prosecution Service. Owen J. D. Clarke, Controller, Scotland, Board of Inland Revenue. Stella Rosemary Clarke, . For services to the Community in Bristol. Betty St. Clair, The Honourable Mrs. Clay. For services to Guiding. John Brian Clayton, Chairman, Bridon plc. For services to Industry and to Export. Donald Thomas Younger Curry, Chairman, Meat and Livestock Commission. For services to Agriculture. William Wentworth Daniel. For services for Industrial Relations. Edward Charles Dart, Research and Development Director, Zeneca Seeds. For services to Industry and to Science. Edmund Leopold de Rothschild, . For charitable services. Nicholas Dampier Deakin. For services to the Commission on the Future of the Voluntary Sector. Anthony Albert Denton, Chairman, Noble Denton International Ltd. For services to Engineering. Roger Joseph Dickens, , Deputy U.K Senior Partner, KPMG. For services to Industry in the West Midlands. Judith Donovan, Chair, Bradford & District Training and Enterprise Council. For services to Training. Olga Lindholm Driver, Senior Partner, Aiking Driver Partnership. For services to ACAS and to Industrial Relations. Francis Cuthbert Duffy. For services to Architecture. Professor John Edwin Enderby, , lately H. O.
Sources: en.wikipedia.org
== Drug interactions == Smoking is known to increase levels of liver enzymes that break down drugs and toxins. That means that drugs cleared by these enzymes are cleared more quickly in smokers, which may result in the drugs not working. Specifically, levels of CYP1A2 and CYP2A6 are induced: substrates for 1A2 include caffeine and tricyclic antidepressants such as amitriptyline; substrates for 2A6 include the anticonvulsant valproic acid.
Transamination is mediated by several types of aminotransferase enzymes. An aminotransferase may be specific for an individual amino acid, or it may be able to process any member of a group of similar ones, for example the branched-chain amino acids, which comprises valine, isoleucine, and leucine. The two common types of aminotransferases are alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
The law of conservation of vis viva was championed by the father and son duo, Johann and Daniel Bernoulli. The former enunciated the principle of virtual work as used in statics in its full generality in 1715, while the latter based his Hydrodynamica, published in 1738, on this single vis viva conservation principle. Daniel's study of loss of vis viva of flowing water led him to formulate Bernoulli's principle, which asserts the loss to be proportional to the change in hydrodynamic pressure. Daniel also formulated the notion of work and efficiency for hydraulic machines; and he gave a kinetic theory of gases, and linked the kinetic energy of gas molecules with the temperature of the gas. This focus on the vis viva by the continental physicists eventually led to the discovery of stationarity principles governing mechanics, such as the D'Alembert's principle, Lagrangian, and Hamiltonian formulations of mechanics.
T helper cells (TH cells) assist other lymphocytes, including the maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages. These cells are also known as CD4+ T cells as they express the CD4 glycoprotein on their surfaces. Helper T cells become activated when they are presented with peptide antigens by MHC class II molecules, which are expressed on the surface of antigen-presenting cells (APCs). Once activated, they divide rapidly and secrete cytokines that regulate or assist the immune response. These cells can differentiate into one of several subtypes, which have different roles. Cytokines direct T cells into particular subtypes.
Politicians are usually targeted for three reasons: (1) Political figures who are honest pose a direct threat to organized crime, and are consequently killed by cartels; (2) Politicians make arrangements to protect a certain cartel and are killed by a rival cartel; and (3) A cartel kills politicians to heat the turf of the rival cartel that operates in the area.
Sources: en.wikipedia.org
Zervas continued his research on peptide synthesis in New York and later in Greece. The first topic of his research once in Greece was the synthesis of N- or O-phosphorylated amino acids, in which he demonstrated the utility of dibenzyl chlorophosphonate. He continued his efforts on the development of new methods within peptide chemistry, including the introduction of the o-nitrophenylsulfenyl (NPS) amino protecting group and peptide synthesis using N-tritylamino acids. One of the major issues which occupied his interests was the chemical synthesis of insulin after its characterisation by Frederick Sanger (1951). The insulin peptide hormone features two protein chains cross-linked by disulfide bridges from cysteine thiols. For this reason, Zervas undertook a systematic study on asymmetric cysteine-containing peptides. In his attempts he introduced new mercaptan protecting groups (e.g. trityl, benzhydryl or benzoyl), which finally made it possible to produce disulfide bridges in a controlled manner. This was a triumph for peptide chemistry in the lab, but could not be possibly scaled to industrial procedures. Building on this work, the first complete synthesis of insulin was simultaneously achieved in 1963 in RWTH Aachen University by Helmut Zahn and in the University of Pittsburgh by Panayotis Katsoyannis, a student of Zervas. Further work on asymmetrical cysteine polypeptides was also done in Athens by Iphigenia Photaki, another student of his.
== Veterinary use == Pethidine provides analgesia for 60 to 90 minutes in the cat and dog. Pethidine is less effective in horses, with IV, SC, and IM administration failing to provide thermal antinociception. Epidural administration of pethidine into the caudal area provided 4-5 hours of analgesia with no cardiovascular depression and only minor sedation. Due to the short duration of analgesia and side effects pethidine is not commonly used with other opioids being used instead. Pethidine is vagolytic but high doses cause bradycardia due to cardiac depression. Pethidine is metabolised by the hepatic enzyme CYP450 via N-demethylation to produce normeperidine. Normeperidine is excitotoxic and can cause myoclonus when too much pethidine is administered. The treatment for these side effects are benzodiazepines. Histamine release following IV administration can cause flare reaction, pruritus, hypersalivation, urination, defaecation, and tachypnoea. IM injection can cause localised oedema and erythema.
=== Porosity of aerogel === There are several ways to determine the porosity of aerogel: the three main methods are gas adsorption, mercury porosimetry, and scattering method. In gas adsorption, nitrogen at its boiling point is adsorbed into the aerogel sample. The gas being adsorbed is dependent on the size of the pores within the sample and on the partial pressure of the gas relative to its saturation pressure. The volume of the gas adsorbed is measured by using the Brunauer, Emmit and Teller formula (BET), which gives the specific surface area of the sample. At high partial pressure in the adsorption/desorption the Kelvin equation gives the pore size distribution of the sample. In mercury porosimetry, the mercury is forced into the aerogel porous system to determine the pores' size, but this method is highly inefficient since the solid frame of aerogel will collapse from the high compressive force. The scattering method involves the angle-dependent deflection of radiation within the aerogel sample. The sample can be solid particles or pores. The radiation goes into the material and determines the fractal geometry of the aerogel pore network. The best radiation wavelengths to use are X-rays and neutrons. Aerogel is also an open porous network: the difference between an open porous network and a closed porous network is that in the open network, gases can enter and leave the substance without any limitation, while a closed porous network traps the gases within the material forcing them to stay within the pores.
== Clinical significance == Mutations in and decreased expression of this protein are associated with amyotrophic lateral sclerosis (ALS). The drug riluzole approved for the treatment of ALS upregulates EAAT2. Ceftriaxone, an antibiotic, has been shown to induce/enhance the expression of EAAT2, resulting in reduced glutamate activity. Ceftriaxone has been shown to reduce the development and expression of tolerance to opiates and other drugs of abuse. EAAT2 may possess an important role in drug addiction and tolerance to addictive drugs. Upregulation of EAAT2 (GLT-1) causes impairment of prepulse inhibition, a sensory gating deficit present in schizophrenics and schizophrenia animal models. Some antipsychotics have been shown to reduce the expression of EAAT2.
During the 18th century, systems of plant identification were developed comparable to dichotomous keys, where unidentified plants are placed into taxonomic groups (e.g. family, genus and species) by making a series of choices between pairs of characters. The choice and sequence of the characters may be artificial in keys designed purely for identification (diagnostic keys) or more closely related to the natural or phyletic order of the taxa in synoptic keys. By the 18th century, unidentified plants were arriving in Europe in increasing numbers from newly explored areas and European colonies. In 1753, Carl Linnaeus published his Species Plantarum, a hierarchical classification of plant species that remains the reference point for modern botanical nomenclature. This established a standardised binomial or two-part naming scheme where the first name represented the genus and the second identified the species within the genus. For the purposes of identification, Linnaeus's Systema Sexuale classified plants into 24 groups according to the number of their male sexual organs. The 24th group, Cryptogamia, included all plants with concealed reproductive parts: mosses, liverworts, ferns, algae and fungi. Increasing knowledge of plant anatomy, morphology and life cycles led to the realisation that there were more natural affinities between plants than the artificial sexual system of Linnaeus.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.